News
Pharma update – 10 July 2020 | Supreme Court decides on pemetrexed & fulvestrant
In this Update we report on two recent judgments of the Dutch Supreme Court. On 12 June 2020 a judgment was rendered on pemetrexed in the interim relief proceedings between Fresenius Kabi Nederland B.V. (“Fresenius”) and Eli Lilly & Company(“Lilly”). On 26 June 2020, the Supreme Court decided on fulvestrant in final relief proceedings between
Read more ›
Pharma update – 8 July 2020 | Confidentiality & Proportionality: New patent case law
In this Update we report on a few developments in Dutch telecom patent cases that have a broader bearing, making them also interesting for the pharma industry. On 13 May 2020, the District Court of The Hague rendered judgment about confidentiality in patent infringement proceedings (DTS v. Samsung). Earlier, on 17 March 2020, the The
Read more ›
IAM Patent 1000 2020: BarentsKrans’ star is rising
IAM has just published the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals – a guide that identifies the top patent professionals in key jurisdictions around the globe. We are proud to report that recommendations from clients and peers have resulted in BarentsKrans’ IP & Technology team ascending to the silver category
Read more ›
Telecoms update | District court imposes confidentiality regime in patent infringement proceedings
On 13 May 2020, the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings between DTS and Samsung regarding the alleged infringement of two of DTS’ European patents. Samsung’s non-infringement defence dealt with security aspects of its mobile devices. Given the sensitive nature of these security aspects, Samsung requested the
Read more ›
Telecoms update | Sisvel denied PI in SEP infringement proceedings against Xiaomi
By decision of 17 March 2020 (only recently published), The Court of Appeal in The Hague (“CoA”) rejected Sisvel’s claim for a PI in interim relief proceedings against Xiaomi re the alleged infringement of its Standard Essential Patent (“SEP”). The CoA confirmed the earlier decision by the Provisions Judge which denied a PI in interim
Read more ›
Great results for BarentsKrans in Legal 500 EMEA
The Legal 500 Europe, Middle East and Africa has just announced its rankings for 2020. As in previous years, BarentsKrans is mentioned several times in this leading guide for the international legal profession. And we’re really proud of this! Background to the Legal 500 rankings Each year, Legal 500 analyses the performance of law firms
Read more ›
Chambers Europe 2020 about BarentsKrans: hyper-intelligent & down to earth
Chambers Europe 2020, the guide that provides an overview of law firms and lawyers in Europe, has just been released. We are very proud to have received numerous honourable mentions once again. BarentsKrans has been ranked in six different practice areas. Ten of our lawyers have been recommended by name. Chambers is one of the
Read more ›
Rankings Chambers Global 2020: again great results for BarentsKrans
Chambers Global 2020 was published today, the guide that provides a global overview of five international jurisdictions. BarentsKrans has a number of wonderful mentions for Corporate/M&A, Intellectual Property and Dispute Resolution. Feedback from clients and peers The yearly Chambers ranking lists are based upon feedback received from clients as well as peer reviews. Chambers is
Read more ›
Telecoms update | Provisions judge denies Fractus a preliminary injunction against Xiaomi et al.
On 10 December 2019, the Provisions Judge of the District Court of The Hague denied a cross-border preliminary injunction claimed by FRACTUS S.A. (‘Fractus’) against Xiaomi Technology Netherlands B.V. (‘Xiaomi’) and several Dutch smartphone vendors for the alleged infringement of Fractus’ patent EP 1 592 083 (‘EP ‘083’). According to Fractus the antennas of various
Read more ›
Pharma Update | Tadalafil dose patent invalid: Court of Appeal confirms judgment 1st instance
The Court of Appeal of The Hague has confirmed the judgment in first instance, in which ICOS’ patent EP 1 173 181 B3 (‘EP ‘181’), claiming a 1-5 mg dosage range for tadalafil, was invalidated. EP ‘181 relates to tadalafil for the treatment of erectile dysfunction in a specific (low) dosage range. This finding was
Read more ›
